Skip to content

Leardngam Herbal Formula vs. Mefenamic acid and Placebo for Primary Dysmenorrhea: A Randomized Controlled Trial on Efficacy

Leardngam Herbal Formula vs. Mefenamic acid and Placebo for Primary Dysmenorrhea: A Randomized Controlled Trial on Efficacy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200608004
Enrollment
240
Registered
2020-06-08
Start date
2020-06-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhea in young adult females dysmenorrhea, young adult, mefenamic acid, herbal medicine, Thai Traditional Medicine, randomized controlled trial

Interventions

The LG group received 1,350 milligrams (3 capsules) of the drug prior to each meal (3 times daily). The beginning started at two days prior to the onset of menstruation.,The LG group received 1,350 mi
Experimental Drug,Experimental Drug,Active Comparator Drug,Active Comparator Drug,Placebo Comparator No treatment,Placebo Comparator No treatment
LG1,LG2,MF1,MF2,PB1,PB2

Sponsors

Department of Thai Traditional and Alternative Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 24 Years

Inclusion criteria

Inclusion criteria: [1]Dysmenorrhea (Numeric rating scale >3) [2]frequency of dysmenorrhea >80% of cycle [3]Regular menstruation [4]No underlying illness [5]No other gynecologic disorders [6]No concurrent of drug; steroid, NSAIDs, anti-platelet, anti-hypertension, magnesium hydroxide, cyclosporin [7]Normal level of laboratory chemistry values [8] No history of drug/herb allery [9] understanding thai language [10] Normal mental status [11] not pregnant status

Exclusion criteria

Exclusion criteria: Medical complication during the trial Drug allery during the trial Abnormal laboratory chemistry values Abnormal finding in pelvis by u/s pregnancy

Design outcomes

Primary

MeasureTime frame
dysmenorrhea intensity at the end of each cycle for three consecutive cycles Numeric rating scale,adverse effect at the end of each cycle for three consecutive cycles questionnaire, Fibser scale

Secondary

MeasureTime frame
Menstrual characteristic at the end of each cycle for three consecutive cycles Questionnaires, and Pictorial Blood Loss Assessment Chart (PBAC)

Countries

Thailand

Contacts

Public ContactTaweelap Tansawadi

Burapha University

Taweetan@buu.ac.th038386554

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026